SpiderRock Advisors LLC Acquires 22 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

SpiderRock Advisors LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,086 shares of the medical research company’s stock after purchasing an additional 22 shares during the quarter. SpiderRock Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,909,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Empowered Funds LLC grew its stake in Thermo Fisher Scientific by 53.3% in the 1st quarter. Empowered Funds LLC now owns 7,704 shares of the medical research company’s stock valued at $4,478,000 after buying an additional 2,677 shares during the last quarter. Atomi Financial Group Inc. grew its stake in Thermo Fisher Scientific by 29.2% in the 1st quarter. Atomi Financial Group Inc. now owns 1,404 shares of the medical research company’s stock valued at $816,000 after buying an additional 317 shares during the last quarter. Concurrent Investment Advisors LLC grew its position in Thermo Fisher Scientific by 9.2% in the 1st quarter. Concurrent Investment Advisors LLC now owns 2,093 shares of the medical research company’s stock worth $1,216,000 after purchasing an additional 176 shares during the last quarter. Choate Investment Advisors grew its position in Thermo Fisher Scientific by 37.1% in the 1st quarter. Choate Investment Advisors now owns 32,544 shares of the medical research company’s stock worth $18,915,000 after purchasing an additional 8,806 shares during the last quarter. Finally, NorthRock Partners LLC grew its position in Thermo Fisher Scientific by 34.4% in the 1st quarter. NorthRock Partners LLC now owns 3,521 shares of the medical research company’s stock worth $2,046,000 after purchasing an additional 902 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on TMO shares. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Stephens started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Finally, Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Trading Down 0.7 %

Shares of NYSE TMO opened at $551.74 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88. The company has a market cap of $211.04 billion, a PE ratio of 34.59, a P/E/G ratio of 3.70 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average of $593.95 and a two-hundred day moving average of $583.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the firm posted $5.69 earnings per share. The company’s revenue was up .2% on a year-over-year basis. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,150 shares of company stock worth $15,676,125 in the last quarter. 0.34% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.